NTP42

NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP) - mediated [Ca2+] mobilization following stimulation of cells with the alternative TP agonist U46619[1]. NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) [2].

Product Specifications

CAS Number

[2055599-51-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ntp42.html

Purity

98.58

Solubility

DMSO : 31.25 mg/mL (ultrasonic)

Smiles

O=S(C1=CC(C#N)=CC=C1OC2=CC(C3=CC=C(OC(F)F)C=C3)=CC=C2)(NC(NC(C)(C)C)=O)=O

Molecular Formula

C25H23F2N3O5S

Molecular Weight

515.53

Precautions

H302, H315, H319, H335

References & Citations

[1]B. Therese KINSELLA, et al. Thromboxane receptor antagonists. WO2016203314A1.|[2]Eamon Mulvaney, et al. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.